Monoclonal antibody discovery with single plasma cell interrogation (SPIN®) technology from immunized animals

Exonbio specializes in advanced antibody discovery technologies, prominently featuring their patented Single Plasma Cell Interrogation (SPIN®) platform. This innovative technology utilizes microfluidic methods to isolate antigen-specific plasma cells, enabling high-throughput screening and comprehensive analysis of the natural antibody repertoire. By focusing on terminally differentiated plasma cells, Exonbio can select high-affinity antibodies with enhanced specificity. The SPIN® platform also allows for the analysis of native paired antibody genes, ensuring a broad spectrum of epitope coverage, particularly leveraging the unique properties of the rabbit immune system.

In addition to their SPIN® technology, Exonbio is dedicated to developing in-vitro diagnostic antibodies aimed at addressing infectious diseases. Their offerings include a wide range of recombinant antibodies and antigens for various pathogens, including SARS-CoV-2, Influenza, and M. Tuberculosis. The company emphasizes the importance of high-affinity monoclonal antibodies for effective diagnostic applications, providing tools for epitope mapping and neutralization assays. Through their commitment to innovation and rapid development timelines, Exonbio aims to support the scientific community in advancing research and therapeutic strategies against infectious diseases.

United States

EXONBIO is a recombinant antibody and recombinant protein company.
SPIN (Single Plasma Cell Interrogation) Technology for rabbit recombinant monoclonal antibody (rrMAb) development.

EXONBIO

Company Details